Thursday, February 25, 2021
Financial News Conference on the Full Year 2020 Results
Bayer delivers robust performance despite pandemic – foundation laid for future growth
- Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & portfolio adj. plus 0.6 percent)
- EBITDA before special items level with prior year at 11.461 billion euros (minus 0.1 percent) – currency effects offset by stringent cost management
- Crop Science and Pharmaceuticals report stable operational business, Consumer Health sees strong growth
- Core earnings per share at 6.39 euros (plus 0.2 percent)
- Earnings per share at minus 10.68 euros (2019: plus 4.17 euros), impacted by litigation provisions and impairments
- Net financial debt improves by 11.8 percent to 30.041 billion euros
- Proposed dividend of 2.00 euros per share (2019: 2.80 euros)
- Portfolio and innovation capabilities strengthened
- Outlook for 2021: positive momentum and solid operational growth – stable earnings at constant currencies
Statements in written form and presentation slides
Recording of the speeches from Werner Baumann and Wolfgang Nickl (dubbed into English):
Audio: Webcast of the speeches with presentation slides
Audio: MP3 of the speeches for download (MP3, 4.4 MB, 25:05 min.)
Recording (partly dubbed into English):
Audio: Webcast with presentation slides
Audio: MP3 of the discussion for download (MP3, 10.6 MB, 60:29 min.)
